

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Next List](#)[Bottom](#)[View Cart](#)*Searching 1976 to present...*

Results of Search in 1976 to present db for:
(AN/Schering AND contraceptive): 74 patents.
Hits 1 through 50 out of 74

09/091,665[Next 50 Hits](#)[Jump To](#)[Refine Search](#)

an/(Schering) and contraceptive and gestagen

PAT.
NO.

- | PAT.
NO. | Title |
|-------------|---|
| 1 | 6,841,548 T Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives |
| 2 | 6,825,329 T Human PEM as a target for birth control and treatment of Alzheimer's disease |
| 3 | 6,794,409 T Use of ER.beta.-selective ligands for regulating fertility and compounds useful therefor |
| 4 | 6,790,853 T Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| 5 | 6,787,531 T Pharmaceutical composition for use as a contraceptive |
| 6 | 6,670,347 T 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring |
| 7 | 6,653,298 T Composition |
| 8 | RE38,253 T Composition for contraception |
| 9 | 6,610,670 T Cyclodextrin-drospirenone inclusion complexes |
| 10 | 6,608,074 T Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| 11 | 6,596,713 T Steroid esters and amides, process for their production and their pharmaceutical use |
| 12 | 6,548,534 T Nonsteroidal gestagens |
| 13 | 6,451,780 T Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding |
| 14 | RE37,838 T Composition for contraception |
| 15 | 6,407,086 T Meiosis regulating compounds |
| 16 | 6,362,237 T Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| 17 | RE37,564 T Composition for contraception |

- 18 [6,344,454](#) **T Nonsteroidal gestagens**
- 19 [6,344,442](#) **T Zona pellucida proteins for contraception**
- 20 [6,340,688](#) **T Contraception method using competitive progesterone antagonists and novel compounds useful therein**
- 21 [6,312,722](#) **T Pharmaceutical combined preparation, kit and method for hormonal contraception**
- 22 [6,245,804](#) **T Nonsteroidal gestagens**
- 23 [6,225,297](#) **T Combination contraceptive**
- 24 [6,177,416](#) **T Oxyiminopregnancarbolactones**
- 25 [6,147,065](#) **T 14-.alpha., 17-.alpha.-C.sub.2 bridged norprogesterone derivatives**
- 26 [6,143,754](#) **T Competitive progesterone antagonist for demand-oriented female birth control**
- 27 [6,043,234](#) **T Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen**
- 28 [6,027,749](#) **T Pharmaceutical combined preparation, kit and method for hormonal contraception**
- 29 [5,980,940](#) **T Pharmaceutical combination preparation for hormonal contraception**
- 30 [5,973,172](#) **T 14-.alpha.,17-.alpha.-C.sub.2 -bridged norprogesterone derivatives**
- 31 [5,958,878](#) **T Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors**
- 32 [5,858,394](#) **T Agent for transdermal administration that contains gestodene esters**
- 33 [5,827,842](#) **T 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivatives**
- 34 [5,824,667](#) **T Composition for contraception**
- 35 [5,756,490](#) **T Pharmaceutical combination preparation for hormonal contraception**
- 36 [5,719,136](#) **T Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women**
- 37 [5,601,814](#) **T Use of IL-6 to treat toxic shock**
- 38 [5,595,970](#) **T Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors**
- 39 [5,569,652](#) **T Dihydrospiorenone as an antiandrogen**
- 40 [5,531,703](#) **T Applicator for semisolid medications**
- 41 [5,529,993](#) **T 14.alpha., 17.alpha.-ethano-16.alpha.-hydroxy-estratrienes**
- 42 [5,439,913](#) **T Contraception method using competitive progesterone antagonists and novel compounds useful therein**
- 43 [4,977,147](#) **T 17-methylene- and 17-ethylidene-estratrienes**
- 44 [4,891,365](#) **T 17-Substituted estradienes and estratrienes**
- 45 [4,794,119](#) **T Aqueous crystalline suspension of steroid glycoesters**
- 46 [4,780,460](#) **T Glycoesters of estradiol and estriol**
- 47 [4,719,054](#) **T Process for the production of 17.alpha.-ethynyl-17.beta.-hydroxy-18-methyl-4,15-estradien-3-one, and novel 3,5-estradien-17-one starting compounds for this process**
- 48 [4,681,875](#) **T 3,17 .beta.-estriol diesters, methods of their use, and pharmaceutical preparations containing them**
- 49 [4,670,427](#) **T 1.alpha.,2.alpha.-methylene-6-methylene- and 6.alpha.-methylpregnenes, their preparation and pharmaceutical use**
- 50 [4,621,079](#) **T Multistage combination preparation and its use for oral contraception**